Incretin Atlas › Trials › China Phase II (obesity, non-diabetic)
China Phase II (obesity, non-diabetic)
HDM1005 · obesity
Design
- Molecule(s)
- HDM1005
- Population
- obesity
- Phase
- 2
- Participants
- 243
- Duration
- 22 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.0 mg | obesity china | 22 | 243 | — | —−13.3 % vs −2.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| 4.0 mg | obesity china | 22 | 243 | — | —−13.3 % vs −2.5 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 2.0 mg · weight_unsp · secondary
2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%
- 4.0 mg · weight_unsp · secondary
2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: China Phase II (obesity, non-diabetic). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/china-phase-ii/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.